Ken Griffin Apellis Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 143,900 shares of APLS stock, worth $3.96 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,900
Previous 218,300
34.08%
Holding current value
$3.96 Million
Previous $8.37 Million
50.44%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding APLS
# of Institutions
309Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$428 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$327 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$305 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$270 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$159 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.02B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...